What does the Tesamorelin + Ipamorelin blend do?
It pairs Tesamorelin (an FDA-approved GHRH-analogue) with Ipamorelin (a selective ghrelin-mimetic), engaging both pituitary GH-release receptor systems with an approved-drug backbone.
Last reviewed 2026-07-13
Read the answer
The Tesamorelin + Ipamorelin blend is similar in pharmacological logic to CJC-1295 + Ipamorelin — a GHRH-analogue paired with a ghrelin-mimetic to engage both pituitary GH-release receptor systems. The distinctive element is Tesamorelin's peer-reviewed evidence base for visceral-fat-reduction pharmacology (Falutz 2007 NEJM, Stanley 2014 JAMA). This gives the GHRH-analogue arm of the blend a stronger evidence base than CJC-1295-based blends.
Tesamorelin's documented research signal is specifically visceral- and hepatic-fat reduction. Its use in the broader research-peptide space extends the mechanism to general GH-secretagogue applications. The pairing with Ipamorelin adds the ghrelin-receptor arm for the same synergistic-GH-release rationale as CJC-1295 + Ipamorelin.
Because Tesamorelin is a longer molecule than CJC-1295 with distinct pharmacokinetics, the blend has a somewhat different dosing pattern than a CJC-1295-based blend. Reference protocols vary, but Tesamorelin's own documented research reference (2 mg subcutaneously daily) provides a starting point for the GHRH-analogue arm. Ipamorelin dosing follows its standard protocol.
Blend-level trial evidence for the specific Tesamorelin + Ipamorelin combination does not exist. As with all blends in this catalog, the pharmacological rationale is coherent but the specific combination has not been formally tested.
Related on Healthy Mango
Related compounds
Related research blends
Related guides
Related comparisons
Related research categories
References
- A phase 3, randomised, placebo-controlled trial of tesamorelin (a growth hormone–releasing factor analogue) in HIV-infected patients with excess abdominal fat· Falutz J, Allas S, Blot K, et al. · 2007
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation — a randomised clinical trial· Stanley TL, Feldpausch MN, Oh J, et al. · 2014
Question
Related questions
Other questions that touch the same biology, evidence, or laboratory concepts.
What are GH secretagogues?
GH secretagogues are peptides that stimulate the pituitary to release growth hormone. They fall into two families: GHRH-analogues (Sermorelin, CJC-1295, Tesamorelin) and ghrelin-mimetics (Ipamorelin, older GHRPs).
What does the CJC-1295 + Ipamorelin blend do?
It pairs a GHRH-analogue (CJC-1295) with a ghrelin-mimetic (Ipamorelin) so both pituitary GH-releasing receptor systems are engaged simultaneously, producing greater GH release than either component alone.
What is Aura and why those three components?
Aura is a research blend of GHK-Cu + BPC-157 + KPV. It combines ECM remodelling (GHK-Cu), vascular supply (BPC-157), and inflammatory control (KPV). Chosen when inflammation-management is a priority.
When would you choose Aura vs Glow vs Klow?
Aura (GHK-Cu+BPC-157+KPV) when inflammation is the priority. Glow (GHK-Cu+BPC-157+TB-500) for skin rejuvenation and structural repair. Klow (all four) when every layer matters.